haloperidol

Haloperidol (Serenace) is a highly potent neuroleptic by relieving nervous through the depression of nerve function. In addition, haloperidol has shown about 50-fold efficacy than chlorpromazine, another antipsychotic drug. Haloperidol has some potencies in the treatment of delusions and hallucinations. Its effects are primarily attained through blocking dopamine receptors in the mesocortex and limbic system.

Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Haloperidol D4' is deuterium-labeled haloperidol. Haloperidol is a dopamine D2 receptor antagonist.

Haloperidol lactate is a potent antipsychotic. haloperidol lactate has potential for studies in psychiatric disorders. haloperidol lactate can be used in acute and chronic schizophrenia and polyarousal syndrome.

Reduced Haloperidol-d4 is a deuterated compound of Reduced Haloperidol. Reduced Haloperidol has a CAS number of 34104-67-1.

Haloperidol decanoate (KD 16) is a typical antipsychotic agent utilized as maintenance treatment for schizophrenia and mood disorders formulated as an ester for intramuscular injection.

Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist which is a potent antipsychotic agent.

Haloperidol D4 is deuterium-labeled haloperidol.

Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid that blocks aortic constriction and antagonizes haloperidol-induced oral motility disorders.

(S)-(-)-MRJF22, a haloperidol metabolite II valproate ester, demonstrates potent antimigratory effects in both endothelial and tumor cells, and is considered a promising multifunctional agent in the treatment of uveal melanoma [1].

VU0477886 is a potent mGlu4 positive allosteric modulator (PAM) with robust efficacy in a standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).

Antibacterial agent 67 significantly inhibited the activity of succinate dehydrogenase with an IC50 value of 0.03 μM and showed significantly higher enzymatic inhibitory activity against succinate dehydrogenase than haloperidol (IC50= 4.40 μM).

Ro 04-5595 is a selective antagonist of NMDA receptors NR2B subunits. Ro 04-5595 had an EC 50 of 186 ± 32 nmol/L. Ro 04-5595 was predicted to bind the EVT-101 binding site, not the ifenprodil-binding site. Specific binding, defined with a new NR2B-specific antagonist Ro 04-5595 at 10 microM was fully inhibited by several compounds with the following rank order of affinities--Ro 25-6981 > CP-101,606 > Ro 04-5595 = ifenprodil >> eliprodil > haloperidol > spermine > spermidine > MgCl2 > CaCl2--and partially inhibited by competitive glutamate recognition site antagonists. Complementary high-resolution autoradiographic images using [3H]Ro04-5595 demonstrated strong binding in NR2B receptor-rich regions and low binding in cerebellum where NR2B concentration is low.

Spiperone (Spiropitan) is a spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.

Acetyl β-endorphin (1-26) is a neuropeptide found in rat hippocampus, brain stem, and pituitary. It is also present in the human hypothalamus, where it comprises approximately 4.9% of total β-endorphin peptides. Acetyl β-endorphin (1-26) is produced through posttranslational processing of β-endorphin and is processed similarly in rat and human hypothalamus. Levels of acetyl β-endorphin (1-26) increase in the rat pars intermedia and brain stem following chronic administration of haloperidol .